HCA Healthcare, Inc. $HCA Stock Holdings Raised by Shell Asset Management Co.

Shell Asset Management Co. increased its holdings in HCA Healthcare, Inc. (NYSE:HCA) by 39.6% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 14,382 shares of the company’s stock after buying an additional 4,081 shares during the period. Shell Asset Management Co.’s holdings in HCA Healthcare were worth $5,510,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of HCA. Nuveen LLC acquired a new position in shares of HCA Healthcare in the 1st quarter valued at about $569,217,000. Pacer Advisors Inc. boosted its stake in HCA Healthcare by 6,237.9% during the 1st quarter. Pacer Advisors Inc. now owns 1,350,933 shares of the company’s stock valued at $466,815,000 after purchasing an additional 1,329,618 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in HCA Healthcare by 83.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,399,372 shares of the company’s stock valued at $829,104,000 after purchasing an additional 1,091,416 shares during the period. Goldman Sachs Group Inc. boosted its stake in HCA Healthcare by 49.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,781,459 shares of the company’s stock valued at $615,583,000 after purchasing an additional 587,036 shares during the period. Finally, Abdiel Capital Advisors LP acquired a new position in HCA Healthcare during the 1st quarter valued at about $164,835,000. 62.73% of the stock is owned by institutional investors and hedge funds.

HCA Healthcare Price Performance

NYSE:HCA opened at $433.83 on Tuesday. The stock has a market cap of $101.51 billion, a P/E ratio of 18.24, a PEG ratio of 1.35 and a beta of 1.40. HCA Healthcare, Inc. has a one year low of $289.98 and a one year high of $435.03. The company has a fifty day moving average price of $399.40 and a 200 day moving average price of $373.65.

HCA Healthcare (NYSE:HCA) last released its earnings results on Friday, July 25th. The company reported $6.84 EPS for the quarter, beating the consensus estimate of $6.20 by $0.64. HCA Healthcare had a net margin of 8.21% and a negative return on equity of 7,363.11%. The firm had revenue of $18.61 billion during the quarter, compared to analysts’ expectations of $18.49 billion. During the same period in the prior year, the company earned $5.50 EPS. The business’s quarterly revenue was up 6.4% compared to the same quarter last year. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. As a group, equities research analysts anticipate that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Tuesday, September 16th were paid a $0.72 dividend. The ex-dividend date was Tuesday, September 16th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.7%. HCA Healthcare’s dividend payout ratio is currently 12.11%.

Insider Activity

In other news, EVP Michael S. Cuffe sold 3,836 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $418.84, for a total value of $1,606,670.24. Following the sale, the executive vice president owned 31,503 shares of the company’s stock, valued at approximately $13,194,716.52. This represents a 10.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on HCA. Wolfe Research lowered shares of HCA Healthcare from an “outperform” rating to a “peer perform” rating in a research note on Monday, July 28th. Bank of America boosted their target price on shares of HCA Healthcare from $375.00 to $410.00 and gave the stock a “neutral” rating in a report on Wednesday, September 10th. Morgan Stanley dropped their target price on shares of HCA Healthcare from $410.00 to $400.00 and set an “equal weight” rating on the stock in a report on Monday, July 28th. JPMorgan Chase & Co. boosted their price target on shares of HCA Healthcare from $360.00 to $370.00 and gave the company a “neutral” rating in a report on Monday, August 4th. Finally, Royal Bank Of Canada cut their price target on shares of HCA Healthcare from $404.00 to $401.00 and set an “outperform” rating on the stock in a report on Monday, July 28th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $407.75.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.